| Client | Europe based mid-market Private Equity firm |
| Situation | Our client was looking to invest in a family-owned pharma CDMO. They engaged with us to leverage our deep expertise in this area and in order to guide them through their investment decision process. |
| Our approach | In addition to analyzing the market dynamics, growth, we conducted a deep dive (during 2-3 weeks) into:
· Customer dependency and potential risks · Current commercial contract analysis · Sources of differentiation versus key competitors · Detailed analysis of management budget and commercial plan · Potential M&A opportunities · Customer referencing |
| Results | Our client could leverage our research with their investment committee and successfully negotiate an agreement with the seller, taking into consideration they key risks and opportunities |
| Client | Mid-market Private Equity firm in Western Europe |
| Situation | Client had recently acquired a CRO focusing on Phase 1-3 clinical trials for Pharma and Biotech customers. They were keen to augment the portfolio company’s capabilities by acquiring complementary assets in the US and also to broaden the services offering |
| Our approach | We leveraged our IP to generate a comprehensive database of CROs offering services that could be considered complementary to the portfolio company. Based on our research, we identified, evaluated and prioritized over 200 add-on targets and initiated contact with selected potential targets. |
| Results | Our client (mid-market private equity fund), managed to close 2 add-on deals for their CRO portfolio company, within a period of one year. |
| Client | Large New York-based Private Equity firm |
| Situation | The healthcare investment team was keen to better understand opportunities in the MedTech contract manufacturing segment. |
| Our approach | Over 4 weeks, our team conducted a deep dive into the medtech contract development and manufacturing segment. Our client was able to get deep insights into the market drivers, attractive sub-segments and profit pools, differentiated services and manufacturing technologies, along with a investor perspective on purchase process, criteria. We also created an investment framework, enabling our client to evaluate new opportunities objectively. |
| Results | The healthcare team was able to evaluate inbound opportunities more effectively and also to source potential transactions. |
